Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solid splenic masses: evaluation with 18F-FDG PET/CT.

Ur Metser1, Elka Miller, Ada Kessler

  • 1Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, 6 Weizman St., Tel-Aviv, 64239 Israel. umetser@tasmc.health.gov.il

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|January 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fetal Brain Abnormalities Following Laser Surgery for Twin-to-Twin Transfusion Syndrome: Imaging Patterns and Evolution.

Prenatal diagnosis·2026
Same author

CAR/CanSPR Practice Guidelines: FAST MRI for Pediatric Neuroimaging.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2026
Same author

Implementation of pediatric and fetal postmortem imaging into clinical practice: a multi-society statement from the ESPR, SPR, SLARP, AOSPR, WFPI, and IAFR.

Pediatric radiology·2026
Same author

Standardised structured fetal and neonatal postmortem magnetic resonance imaging reporting: recommendations from the European Society of Paediatric Radiology Postmortem Task Force.

Pediatric radiology·2026
Same author

Neuroimaging Findings and Risk Factors for Brain Injury in Foetuses Treated for Anaemia.

Prenatal diagnosis·2026
Same author

Pathogenic variants in BORCS5 cause a spectrum of neurodevelopmental and neurodegenerative disorders with lysosomal dysfunction.

The Journal of clinical investigation·2026

18F-FDG PET/CT accurately distinguishes benign from malignant splenic masses in patients with known cancer. For incidental splenic lesions, this imaging technique shows high negative predictive value, prompting further evaluation of suspicious findings.

Area of Science:

  • Nuclear Medicine
  • Radiology
  • Oncology

Background:

  • Solid splenic masses can be challenging to diagnose.
  • Differentiating benign from malignant splenic lesions is crucial for patient management.

Purpose of the Study:

  • To evaluate the effectiveness of 18F-FDG PET/CT in assessing solid splenic masses.
  • To compare diagnostic performance in patients with and without known malignancy.

Main Methods:

  • Retrospective analysis of 88 patients (68 with known malignancy, 20 without).
  • Assessed lesion size, number, and 18F-FDG uptake (SUV).
  • Histology or imaging/clinical follow-up served as the reference standard.

Main Results:

  • 18F-FDG PET/CT demonstrated 100% sensitivity and specificity in patients with known malignancy.

Related Experiment Videos

  • In patients without known malignancy, diagnostic performance was 100% sensitivity, 83% specificity, 80% PPV, and 100% NPV.
  • An SUV threshold of 2.3 effectively differentiated lesions in patients with known malignancy.

    • Conclusions:

    • 18F-FDG PET/CT reliably differentiates benign from malignant splenic masses in patients with known malignancy.
    • The test shows high negative predictive value for incidental splenic masses.
    • 80% of incidentally found splenic masses in patients without known malignancy were malignant, warranting further investigation.